Q/C TECHNOLOGIES, INC.
QCLSNasdaq
$3.44
↑ +4.2%Jul 17 close · end-of-day
Price
1Y↓ -68.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$27.7M
Enterprise Value
$14.7M
P/E
—
P/S
—
P/B
1.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$11.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-56.7%
ROIC
-94.2%
Debt / Equity
—
Net Cash
$13.0M
Return 1Y
-63.7%
Company profile
TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
- CEO
- Mitchell Glass
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 6
- Headquarters
- Maryland
- Website
- tnfpharma.com
Management & directors
- Silverman JoshuaExecutive Chairman
- Glass MitchellDirector, Chief Medical Off.
Roles derived from SEC Form 4 filings.
Earnings
QCLS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.19↓ -47.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$9.5M | -$28.8M | -$15.3M | -$17.1M | -$10.2M | -$9.8M |
| Net income | -$9.5M | -$29.9M | -$15.2M | -$4.0M | -$23.4M | -$11.6M |
| Diluted EPS | — | — | -$11.74 | -$5.33 | -$1,080.87 | -$8.66 |
| Operating cash flow | -$4.7M | -$19.5M | -$12.3M | -$13.0M | -$9.0M | -$9.1M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.4M | -$1.8M | -$2.2M | -$2.5M | -$1.9M | -$1.8M | -$3.7M | -$1.9M |
| Net income | -$9.6M | -$1.9M | -$2.1M | -$1.1M | -$1.8M | -$2.8M | -$5.9M | -$1.2M |
| Diluted EPS | -$4.54 | -$107.62 | -$963.57 | -$0.36 | -$0.18 | -$2.50 | -$5.62 | -$0.19 |
| Operating cash flow | -$2.7M | -$2.4M | -$2.1M | -$2.6M | -$2.1M | -$1.2M | -$3.2M | -$3.3M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Sep 17, 2025
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-13 | Silverman Joshua· Executive Chairman | Award | 162,162 | $0.00 | $0.00 | filing |
| 2026-03-30 | Voss Chelsea Sierra | Buy | 1,753 | $3.15 | $5,521.95 | filing |
| 2026-01-16 | Voss Chelsea Sierra | Award | 212,500 | $0.00 | $0.00 | filing |
| 2026-01-16 | Voss Chelsea Sierra | Award | 25,000 | $0.00 | $0.00 | filing |
| 2025-11-14 | Glass Mitchell· Director, Chief Medical Off. | Award | 11,420 | $0.00 | $0.00 | filing |
| 2025-11-14 | White Billy Joe | Award | 22,839 | $0.00 | $0.00 | filing |
| 2025-11-14 | Silverman Joshua· Executive Chairman | Award | 91,356 | $0.00 | $0.00 | filing |
| 2025-11-14 | Friscia Stephen | Award | 22,839 | $0.00 | $0.00 | filing |
| 2025-11-14 | Bernstein Bruce | Award | 25,000 | $0.00 | $0.00 | filing |
| 2025-11-14 | RAUCH GARY M | Award | 11,420 | $0.00 | $0.00 | filing |
| 2025-10-03 | Silverman Joshua· Executive Chairman | Award | 8,644 | $0.00 | $0.00 | filing |
| 2025-10-03 | Friscia Stephen | Award | 2,161 | $0.00 | $0.00 | filing |
| 2025-10-03 | Glass Mitchell· Director, Chief Medical Off. | Award | 1,080 | $0.00 | $0.00 | filing |
| 2025-10-03 | White Billy Joe | Award | 2,161 | $0.00 | $0.00 | filing |
| 2025-10-03 | RAUCH GARY M | Award | 1,080 | $0.00 | $0.00 | filing |
Latest 15 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.